To provide total clinical solutions
Integration of two European group companies to strengthen analytical and measurement reagent business

Shimadzu will merge its reagent company, Alsachim SAS (France, abbreviated as ALC), as the absorbing company with Biomaneo SAS (France, abbreviated as BMO), as the absorbed company and change its name to Shimadzu Chemistry and Diagnostics SAS (France, abbreviated as SCHD) on April 1, 2025.

Alsachim develops and manufactures reagent kits for liquid chromatography-mass spectrometry (LC-MS) and stable isotope reagents, while Biomaneo develops and manufactures clinical software and reagent kits for matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-MS). Both companies possess technologies that are essential for the growth of our group's clinical LC-MS business and will create synergies and strengthen governance through management integration.

SCHD, the new company, will consolidate the businesses of ALC and BMO into a single entity to enhance development functions that meet customer needs. In addition, SCHD will accelerate the global expansion of comprehensive clinical solutions, including LC-MS, reagent kits, and software, through collaboration with Shimadzu headquarters. Shimadzu will continue to provide comprehensive clinical solutions that combine SCHD products with its own LC-MS and MALDI-MS.

Overview of the New Company

• Name ：Shimadzu Chemistry and Diagnostics SAS (abbreviated as SCHD)
  (100% investment in our company)
• Head Office ：Strasbourg, France
• Date of Integration ：April 1, 2025
• President ：Kunihiko Koriyama
• Number of Employees ：76 (as of the date of integration)